Overview: Maternal Screen 2 Dual TRACE Panel
Introduction: The Maternal Screen 2 Dual TRACE Panel is a diagnostic tool designed to screen for fetal abnormalities using serum samples. In India, first-trimester combined screening (free beta-hCG + PAPP-A + nuchal translucency) detects ~85-90 percent of Down syndrome (trisomy 21) cases, with prevalence ~1 in 800-1000 live births; under-screening is common in rural/low-SES pregnancies due to limited access to ultrasound/biochemistry labs. High morbidity from missed aneuploidy leading to late diagnosis, increased birth defects burden, or emotional/financial strain on families. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society of Perinatology and Reproductive Medicine guidelines, the test employs immunoassay for free beta-hCG and PAPP-A, combined with NT measurement and maternal age for risk assessment over 1-2 days with high accuracy, valuable for early trisomy 21/18/13 screening (11-13+6 weeks). This diagnostic falls under prenatal screening and targets pregnant women in first trimester, addressing accurate detection to guide CVS/NIPT or continuation counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling early risk stratification and reducing Down syndrome birth rates through informed choices. Its serum-based approach ensures reliable biochemical component.
Other Names: Mat Scr 2 TRACE Pnl.
FDA Status: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.
Historical Milestone: Dual marker + NT standard since 2000s; in India, scaled under maternal health programs.
Purpose: The test assesses 5 parameters including free beta-hCG to guide fetal abnormality screening, calculate trisomy risk, inform invasive testing.
Test Parameters: 1. Free Beta-hCG, 2. PAPP-A, 3. NT, 4. Risk Assessment, 5. Maternal Age.
Pretest Condition: No fasting required; patients should be 11-13+6 weeks gestation with NT scan.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on gestational age, NT measurement, maternal age.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of false-positive/negative including anxiety or missed diagnosis, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate risk using FMF algorithm within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect gestational age can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High risk (>1:250) indicates need for diagnostic testing, necessitating specialist input.
Specialist Consultation: Fetal medicine specialists or obstetricians should be consulted for management.
Additional Supporting Tests: NIPT, CVS for confirmation.
Test Limitations: Screening only (not diagnostic); comprehensive approach required.
References: Indian Journal of Obstetrics and Gynaecology 2024, Prenatal Studies India 2023.
